
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
A discussion on the management of a 64-year-old man with differentiated thyroid cancer, with special consider of the phase 3 SELECT trial regimen.
Case Information: A 64-Year-Old Man With Differentiated Thyroid Cancer
Initial Presentation
Clinical Workup and Initial Treatment
Subsequent Treatment and Follow-up






